PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
Elizabeth P DargaEmily M DolceFang FangKelley M KidwellChristina L GerschSteven KregelDafydd G ThomasAnoop GillMartha E BrownSteven GrossMark ConnellyMichael A HolinstatErin F CobainJames M RaeDaniel F HayesCostanza PaolettiPublished in: PloS one (2021)
PD-L1 expression was found in metastatic breast cancer patients on both CTC and platelets in an independent fashion. Inter-patient platelet PD-L1 expression was highly heterogeneous suggesting that it is a biological event associated with cancer in some but not all patients. Taken together, our data suggest that CTC and platelet PD-L1 expression could play a role in predicting which patients should receive immune checkpoint inhibition and as a pharmacodynamics biomarker during treatment.
Keyphrases
- end stage renal disease
- circulating tumor cells
- ejection fraction
- metastatic breast cancer
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- squamous cell carcinoma
- machine learning
- young adults
- electronic health record
- papillary thyroid
- artificial intelligence
- deep learning
- lymph node metastasis
- red blood cell